TOP1 and cancer: These findings highlight that MYC level might be the predictive biomarker to identify cancers sensitive to TOP1 inhibitors.[71] We found a significant correlation between ETV4 expression and R‐loop‐induced DSBs in NSCLC cells upon CPT treatment.